Abstract:Ethnopharmacological relevance: Catalpol is made from the root of Rehmannia glutinosa, a plant often used to treat a variety of diseases of the central nervous system in traditional Chinese medicine, such as Dementia, Apoplexy and Parkinson. According to the recent studies, catalpol can attenuate nerve damage by inhibiting neuroinflammation.Aim of the study: In this research, we examined catalopol's impact on neuroinflammation in LPS-induced BV2 cells, ulteriorly assessed the mechanism of the inflammasome.Materials and methods: BV2 cells were induced by LPS to build the neuroinflammatory model in vitro. The best time for LPS to induce the initial stage of neuroinflammation was screening by cell viability (CCK-8). Then the successful construction of the model were verified by cell morphology (optical microscope), and release of inflammatory factors (PCR).Further, catalpol was used for neuroinflammation intervention. The best intervention time of catalpol was screening by cell viability (CCK-8). BV2 cells were exposed to LPS and treated with catalpol (10μM, 100μM, 1000μM) for 24h. The better intervention concentration of catalpol against neuroinflammation was determined through cell viability (CCK-8), cell morphology (optical microscope), and release of inflammatory cytokines (IL-6) (PCR). Then the action of catalpol on LPS-induced BV2 cells polarization was evaluated by M1 (CD86) and M2 (CD206) phenotypic markers of BV2 polarization (WB, FCM). Finally, the mechanism of catalpol against neuroinflammation through NLRP3 inflammasome signal pathway was studied. The signal pathway of anti-inflammatory mechanism of catalpol was evaluated by the expression of NLRP3 inflammasome complex proteins (NLRP3、ASC and caspase-1) (WB、IF) and its upstream target (NF-κB) (WB), and its downriver effector inflammatory cytokines (IL-18、IL-1β) (PCR).Results: In contrast to the LPS group, the catalpol group's BV2 cell activity, length and number of cell branches, and production of IL-6 were all obviously attenusted. Moreover, the CD86 expression was enhanced by LPS and inhibited by catalpol, yet there was no discernible impact from CD206 expression. Further investigation revealed that the catalpol group's NF-κB、NLRP3、ASC、caspase-1、IL-18 and IL-1β expression were much lower than that of the model group.Conclusion: Catalpol has anti-inflammatory effect and inhibites the polarization of pro-inflammatory phenotype of microglia, but has no discernible impact on the polarization of anti-inflammatory phenotype. Catalpol attenuates neuroinflammation by preventing the NF-κB/NLRP3 inflammasome signaling path from becoming activated.

Catalpol rescues LPS-induced cognitive impairment via inhibition of NF-Κb-regulated neuroinflammation and up-regulation of TrkB-mediated BDNF secretion in mice

Catalpol reduced LPS induced BV2 immunoreactivity through NF-κB/NLRP3 pathways: an in Vitro and in silico study

Catalpol Inhibits LPS-Induced Neuroinflammation and Alleviates the Activation of NLRP3 Inflammasome in Microglia

Catalpol Restores Lps-Elicited Rat Microcirculation Disorder By Regulation Of A Network Of Signaling Involving Inhibition Of Tlr-4 And Src

Effects of Catalpol on Mitochondrial Function and Working Memory in Mice after Lipopolysaccharide-Induced Acute Systemic Inflammation

Catalpol rescues cognitive deficits by attenuating amyloid β plaques and neuroinflammation

NU9056, a KAT 5 Inhibitor, Treatment Alleviates Brain Dysfunction by Inhibiting NLRP3 Inflammasome Activation, Affecting Gut Microbiota, and Derived Metabolites in LPS-Treated Mice

Catalpol attenuates ischemic stroke by promoting neurogenesis and angiogenesis via the SDF-1α/CXCR4 pathway

Catalpol Induces Neuroprotection and Prevents Memory Dysfunction through the Cholinergic System and BDNF.

Catalpol ameliorates depressive-like behaviors in CUMS mice via oxidative stress-mediated NLRP3 inflammasome and neuroinflammation

Catalpol Enhances Neurogenesis and Inhibits Apoptosis of New Neurons Via BDNF, but Not the BDNF/Trkb Pathway

Catalpol Up-Regulates Expression of BDNF and TrkB Proteins Within the Peri-Infarct Cortex in Rats with Focal Cerebral Ischemia

Neuroprotective activities of catalpol against CaMKII-dependent apoptosis induced by LPS in PC12 cells.

Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures

Catalpol Alleviates Ischemic Stroke Through Promoting Angiogenesis and Facilitating Proliferation and Differentiation of Neural Stem Cells via the VEGF-A/KDR Pathway

RhoA/ROCK-2 Pathway Inhibition and Tight Junction Protein Upregulation by Catalpol Suppresses Lipopolysaccaride-Induced Disruption of Blood-Brain Barrier Permeability

Catalpol inhibits LPS plus IFN-γ-induced inflammatory response in astrocytes primary cultures.

Neuroprotective properties of catalpol in transient global cerebral ischemia in gerbils: dose–response, therapeutic time-window and long-term efficacy

Catalpol up-regulated GAP-43 protein expression and improved behavior outcome of focal cerebral ischemia rats

Catalpol induces cell activity to promote axonal regeneration via the PI3K/AKT/mTOR pathway in vivo and in vitro stroke model.

Catalpol Prevents the Loss of CA1 Hippocampal Neurons and Reduces Working Errors in Gerbils after Ischemia-Reperfusion Injury